Diabetic Neuropathy Market 2022 Driving Factors Forecast Research 2028
Diabetic Neuropathy Market |
Diabetes-related nerve degeneration, or diabetic neuropathy,
frequently causes discomfort and numbness in the feet or lower legs. Depending
on how neuropathy affects the body, pain may also be felt in other areas,
including the wrist, hips, and back. There are numerous varieties of
neuropathy, including autonomic, proximal, peripheral, and focal neuropathy.
Diabetic neuropathy is thought to affect 50% of people with diabetes worldwide.
Additionally, according to CDC estimates, 6-7 Americans per 1000 patients with
diabetes have diabetic neuropathy. The patient pool for diabetic neuropathy
will grow dramatically as a result of the ageing population and rising diabetes
incidence, which will also propel the Diabetic Neuropathy
Market expansion.
The previous five years have seen a consistent progression in
diabetes. The disorder-related discomfort can be treated with a variety of
generic and specialist medications, such as antidepressants and antispasmodics.
However, 79 unique medications were evaluated to be in the clinical trial stage
with Horizant in 2011. The pharmaceutical industry will carry out the essential
research and release brand-new medications in several important nations. In
addition, rising healthcare costs, higher pharmaceutical R&D spending, and
increased awareness of diabetic neuropathy will all play significant roles in
the Diabetic Neuropathy Market expansion.
Major participants in the Diabetic Neuropathy Market are more actively involved in
product launches and approvals. For instance, Pfizer, Inc. gained FDA approval
from the United States in October 2017 for LYRICA CR extended release tablets,
which were intended to be taken once daily. These pills are intended to treat
peripheral diabetic neuropathy-related neuropathic pain. Additionally, in July
2020, the U.S. FDA approved QUTENZA (capsaicin) 8% patch, a topical,
non-systemic, non-opioid pain reliever that is applied as a patch, from
Grünenthal's U.S. subsidiary Averitas Pharma, Inc. It is the first treatment of
its kind that uses a prescription-strength form of capsaicin to penetrate the
skin and treat adult patients with neuropathic pain associated with diabetic
peripheral neuropathy (DPN) of the feet.
Various Segments of Diabetic
Neuropathy Market-
End-User
·
Hospitals
·
Research
Institutes
·
Specialty
Clinics
Distribution Channel
·
Hospital
Pharmacy
·
Retail
Pharmacy
·
Online
Pharmacies
·
Others
The rise in obesity rates due to poor food and sedentary
lifestyles, as well as increased knowledge of diabetes diagnosis and treatment,
are the main factors driving the global Diabetic Neuropathy Market. However, the high cost of diabetic
neuropathy treatment and pharmacological adverse effects limit market
expansion. On the other hand, the increased demand for superior neuropathy
medications is anticipated to offer a wide range of chances for market
expansion in the near future.
Top Manufacturers are GlaxoSmithKline, Pfizer, Johnson
& Johnson, Janssen Pharmaceuticals, and Eli Lilly and Company
Comments
Post a Comment